Table 2 Effects of sub-chronic agmatine treatment on organ weight.

From: Safety and neurochemical profiles of acute and sub-chronic oral treatment with agmatine sulfate

Organ/body weight ratio

Brain

Heart

Kidney*

Liver

Spleen

Testicle

WT (Agm-0)

10.96 ± 0.37

3.97 ± 0.19

6.74 ± 0.46

47.11 ± 1.48

2.75 ± 0.14

2.30 ± 0.11

WT (Agm-300)

11.53 ± 0.38

4.21 ± 0.17

6.58 ± 0.22

43.27 ± 1.52

2.45 ± 0.14

2.29 ± 0.10

Tg (Agm-0)

10.63 ± 0.23

3.83 ± 0.09

5.82 ± 0.28

47.20 ± 1.55

2.69 ± 0.20

2.49 ± 0.13

Tg (Agm-300)

10.62 ± 0.29

3.77 ± 0.1

5.50 ± 0.22

47.93 ± 1.89

2.58 ± 0.19

2.22 ± 0.08

  1. Mean (± SEM) organ (mg)/body (g) ratio of the whole brain, heart, kidney, liver, spleen or testicle in wildtype (WT) and APP/PS1 (Tg) mice with oral administration of agmatine sulfate at 0 (Agm-0) or 300 (Agm-300) mg/kg (n = 13–16/group). The organs were collected on day 105 (24 hours after the final dosing).
  2. *Indicates a significant genotype difference in kidney (see section 3.2.4. for details).
Back to article page